全文获取类型
收费全文 | 730篇 |
免费 | 76篇 |
国内免费 | 69篇 |
出版年
2023年 | 8篇 |
2022年 | 11篇 |
2021年 | 20篇 |
2020年 | 22篇 |
2019年 | 27篇 |
2018年 | 20篇 |
2017年 | 18篇 |
2016年 | 24篇 |
2015年 | 30篇 |
2014年 | 40篇 |
2013年 | 61篇 |
2012年 | 19篇 |
2011年 | 25篇 |
2010年 | 21篇 |
2009年 | 44篇 |
2008年 | 47篇 |
2007年 | 42篇 |
2006年 | 51篇 |
2005年 | 49篇 |
2004年 | 37篇 |
2003年 | 44篇 |
2002年 | 26篇 |
2001年 | 28篇 |
2000年 | 16篇 |
1999年 | 23篇 |
1998年 | 21篇 |
1997年 | 14篇 |
1996年 | 9篇 |
1995年 | 15篇 |
1994年 | 11篇 |
1993年 | 7篇 |
1992年 | 18篇 |
1991年 | 8篇 |
1990年 | 7篇 |
1989年 | 2篇 |
1988年 | 6篇 |
1985年 | 3篇 |
1978年 | 1篇 |
排序方式: 共有875条查询结果,搜索用时 203 毫秒
1.
2.
3.
T. Noelle Lombana Jack Bevers III Amy M. Berkley Evangeline Toy Ryan Cook 《MABS-AUSTIN》2019,11(1):75-93
As an immune evasion strategy, MICA and MICB, the major histocompatibility complex class I homologs, are proteolytically cleaved from the surface of cancer cells leading to impairment of CD8 + T cell- and natural killer cell-mediated immune responses. Antibodies that inhibit MICA/B shedding from tumors have therapeutic potential, but the optimal epitopes are unknown. Therefore, we developed a high-resolution, high-throughput glycosylation-engineered epitope mapping (GEM) method, which utilizes site-specific insertion of N-linked glycans onto the antigen surface to mask local regions. We apply GEM to the discovery of epitopes important for shedding inhibition of MICA/B and validate the epitopes at the residue level by alanine scanning and X-ray crystallography (Protein Data Bank accession numbers 6DDM (1D5 Fab-MICA*008), 6DDR (13A9 Fab-MICA*008), 6DDV (6E1 Fab-MICA*008). Furthermore, we show that potent inhibition of MICA shedding can be achieved by antibodies that bind GEM epitopes adjacent to previously reported cleavage sites, and that these anti-MICA/B antibodies can prevent tumor growth in vivo. 相似文献
4.
5.
《Cell》2021,184(22):5593-5607.e18
6.
Paliakkara L. Jaison Vadakkedath M. Kannan Mandagini Geetha Padinjaradath S. Appukuttan 《Journal of biosciences》1993,18(2):187-193
Naturally occurring serum IgG against terminal α-galactoside epitopes (anti-Gal), present exclusively in man, apes and old
world monkeys, was used as probe for these epitopes in human brain. Human brain grey matter soluble glycoproteins enriched
inα galactosyl groups by affinity chromatography on jacalin-sepharose, specifically binds to human anti-Gal in immuno dot
blots. Anti-Gal recognized exclusively the terminal α galactoside epitope in human brain glycoproteins since binding was abolished
by the presence of 1-0-methyl α-D-galactopyranoside as well as by pretreatment of glycoproteins with coffee bean α-galactosidase.
Anti-Gal-peroxidase staining of jacalin-binding human brain glycoproteins in western immuno blots revealed mainly five anti-Gal-binding
polypeptides withM
r
(in kDa) of 94, 108, 180, 210 and 230 respectively. Since the presence of anti-Gal in higher animals accompanies suppression
of the corresponding epitope in most tissues, apparently to maintain immunological balance, possible implications of the above
observation for autoimmunity, tumor metastasis and infection are discussed. 相似文献
7.
《Cell cycle (Georgetown, Tex.)》2013,12(7):1455-1467
Members of the ErbB receptor family are targets of a growing numbers of small molecules and monoclonal antibodies inhibitors currently under development for the treatment of cancer. Although historical efforts have been directed against ErbB1 (EGFR) and ErbB2 (HER2/neu), emerging evidences have pointed to ErbB3 as a key node in the activation of proliferation/survival pathways from the ErbB receptor family and have fueled enthusiasm toward the clinical development of anti-ErbB3 agents. In this study, we have evaluated the potential therapeutic efficacy of a set of three recently generated anti-human ErbB3 monoclonals, A2, A3 and A4, in human primary melanoma cells. We show that in melanoma cells expressing ErbB1, ErbB3 and ErbB4 but not ErbB2 receptor ligands activate the PI3K/AKT pathway, and this leads to increased cell proliferation and migration. While antibodies A3 and A4 are able to potently inhibit ligand-induced signaling, proliferation and migration, antibody A2 is unable to exert this effect. In attempt to understand the mechanism of action and the basis of this different behavior, we demonstrate, through a series of combined approaches, that antibody efficacy strongly correlates with antibody-induced receptor internalization, degradation and inhibition of receptor recycling to the cell surface. Finally, fine epitope mapping studies through a peptide array show that inhibiting vs. non-inhibiting antibodies have a dramatically different mode of binding to the to the receptor extracellular domain. Our study confirms the key role of ErbB3 and points to exploitation of novel combination therapies for treatment of malignant melanoma. 相似文献
8.
《Bioscience, biotechnology, and biochemistry》2013,77(7):1181-1182
The epitopes of the major soybean allergen, Gly m Bd 30K, recognized by mouse monoclonal antibodies H6 and F5 were investigated by using synthetic peptides bound to pins. The epitopes are shown to be localized in peptide 31QGGCGRGWAFSATGAI-EA48 for H6, and in 115 DKVTIDGYETLIMSDEST132 for F5. 相似文献
9.
人乳头瘤病毒11型L1主要衣壳蛋白的B细胞表位多肽作为疫苗的研究 总被引:2,自引:0,他引:2
分析了人乳头瘤病毒11型(HPV11)L1主要衣壳蛋白的B细胞优势表位,并以此为基础研制表位多肽疫苗。研究中采用Goldkey和.PC/Gene软件系统,分析HPV11的L1主要衣壳蛋白的二级结构、抗原性、B细胞表位,并引人氨基酸抗原性指数,综合评估其B细胞优势表位。Fmoc固相合成表位多肽,高效液相层析方法纯化,毛细管电泳分析其纯度。与0.2ml佐剂完全乳化后,按50μg/只的剂量免疫小鼠,进行动物水平的免疫效果评价。取免疫小鼠血清,与HPV11 DNA阳性的尖锐湿疣患者的疣体上清液结合,鉴定免疫后小鼠所产生抗体的特异性。发现HPV11的L1主要衣壳蛋白的第426~439位和第487~501位具有较高的免疫原性,可明显诱导小鼠血清抗体滴度升高,且该抗体与人尖锐湿疣的疣体组织上清液呈阳性反应。说明所选这两个肽段为HPV11的L1主要衣壳蛋白的B细胞优势表位,但是否具有功能特异性,尚需进一步研究。 相似文献
10.
构建汉滩病毒76—118N蛋白及其分别从N-端和C-端缺失的共6个突变体,在大肠杆菌BL-21中进行表达,并对其中一些蛋白进行了纯化。通过Western blot、酶联免疫吸附试验(ELISA)进行汉滩病毒N蛋白的抗原表位分析,N蛋白及6个缺失突变体都与组特异性抗体L13F3呈阳性反应,而缺失突变体与型特异性抗体AH30呈阴性反应。构建汉滩病毒76—118N蛋白及其6个缺失突变体的真核表达载体,并在COS-7细胞中进行表达。通过间接免疫荧光试验(IFA)进行汉滩病毒N蛋白的抗原表位分析,病人血清与真核表达的N蛋白及6个缺失突变体呈阳性反应。而仅有N蛋白及缺失N端1~30位氨基酸序列的NPN30与型特异性抗体AH30呈阳性反应。证实组特异性抗体L13F3结合的抗原表位位于N端1~30位氨基酸;而C端抗原表位对于型特异性抗体AH30与N蛋白的识别和结合具有重要意义,缺失N端100位氨基酸序列可能破坏羧基端构象型表位,也可以影响N蛋白与AH30的结合。 相似文献